Physician profile
Asim Pati
NPI 1841294121
$36,657.13
in general payments reported to CMS, 2019-2025
70 companies · $5,077 in 2025
The $5,077 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,814 · 2020: $8,035 · 2021: $433 · 2022: $4,927 · 2023: $8,330 · 2024: $3,041 · 2025: $5,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,194 · Consulting Fee: $6,368 · Travel and Lodging: $787 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,194.11 |
| Consulting Fee | $6,368.00 |
| Travel and Lodging | $787.32 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,908.36 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Genzyme Corporation | $5,323.87 | 2019-2025 | |
| Incyte Corporation | $4,282.40 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Celgene Corporation | $3,052.41 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Beigene USA, INC. | $2,039.27 | 2020-2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $1,872.32 | 2022-2025 | |
| Abbvie INC. | $1,482.51 | 2019-2025 | |
| Kite Pharma, INC. | $1,447.30 | 2020-2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $862.76 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $789.33 | 2019-2025 | |
| Janssen Biotech, INC. | $764.40 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| Genentech USA, INC. | $694.65 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Pfizer INC. | $686.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $619.37 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $542.73 | 2019-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, LTD. | $450.00 | 2020 | |
| Daiichi Sankyo INC. | $447.87 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $388.89 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Seagen INC. | $376.28 | 2020-2025 | Adcetris, Padcev, Tukysa |
| Astellas Pharma US INC | $282.14 | 2019-2025 | Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $251.27 | 2019-2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $245.07 | 2019-2024 | Onivyde, Somatuline Depot |
| Amgen INC. | $239.37 | 2019-2023 | Blincyto, Kyprolis |
| Taiho Oncology, INC. | $226.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $214.10 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Sobi, INC | $191.04 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $179.65 | 2022-2025 | Fotivda |
| Array Biopharma INC | $173.55 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $167.79 | 2023-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $163.54 | 2021-2025 | Xpovio |
| Exelixis INC. | $154.38 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $154.11 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Kyowa Kirin, INC. | $152.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $140.51 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $130.51 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $128.67 | 2022-2024 | Zepzelca |
| Beone Medicines USA, INC. | $111.19 | 2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $105.32 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmaessentia USA Corporation | $101.76 | 2024-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.19 | 2022-2025 | |
| G1 Therapeutics, INC. | $85.37 | 2022-2023 | Cosela |
| Amag Pharmaceuticals, INC. | $74.29 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $70.12 | 2021-2022 | |
| Adc Therapeutics America, INC. | $62.54 | 2025 | |
| Adaptive Biotechnologies Corporation | $59.52 | 2024-2025 | Clonoseq |
| Coherus Oncology, INC. | $55.56 | 2022 | |
| Mirati Therapeutics, INC. | $51.45 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $47.97 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $47.20 | 2023-2024 | Qinlock |
| Epizyme, INC. | $46.54 | 2022 | |
| Geron Corporation | $44.83 | 2025 | Rytelo |
| Sirtex Medical INC | $33.05 | 2019-2020 | |
| Tersera Therapeutics LLC | $31.20 | 2019 | |
| Secura Bio, INC. | $30.98 | 2020 | |
| Emd Serono, INC. | $29.95 | 2023 | Tepmetko |
| Legend Biotech USA INC. | $28.42 | 2025 | Carvykti |
| Lexicon Pharmaceuticals, INC. | $24.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.64 | 2019-2024 | Xarelto |
| Cti Biopharma Corp. | $21.84 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $21.74 | 2024 | Vivimusta |
| Tesaro, INC. | $19.70 | 2019 | |
| Syndax Pharmaceuticals, INC. | $19.06 | 2025 | |
| Verastem, INC. | $15.24 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.01 | 2024 | Cosela |
| Blueprint Medicines Corporation | $14.02 | 2020 | |
| Springworks Therapeutics, INC. | $14.01 | 2025 | Gomekli |
| Dova Pharmaceuticals | $13.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.90 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Pati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.